Page values for "Clozapine"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Clozapine |
| brand | String | Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements. |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Second-generation neuroleptics|Second-generation neuroleptic (atypical)]] • [[:Category:Neuroleptics|Neuroleptic]] • [[:Category:REMS medicines|REMS medicine (mandatory ANC monitoring)]] • [[:Category:Treatment-resistant schizophrenia medicines|Treatment-resistant schizophrenia medicine]] |
| mechanism | String | '"`UNIQ--vote-00000049-QINU`"' |
| uses | String | |
| starting_dose | String | 12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL. |
| preparations | String | Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available. |
| fda_max | String | 900 mg/day (split into BID or TID dosing). Clinical practice rarely exceeds 600 mg/day; seizure risk increases substantially above 600 mg/day and requires consideration of prophylactic anticonvulsant.'"`UNIQ--ref-0000004A-QINU`"' |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral only. No parenteral formulation (a major limitation in acute agitation requiring rapid tranquilization). |
| onset | String | Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels. |
| duration | String | Due to the half-life of 12 hours (wide range), dosing is BID or TID. Once-daily dosing produces higher peak/trough fluctuations and is generally not used except for a single end-of-day dose in stable patients. |
| halflife | String | |
| bioavailability | String | Approximately 50-60% (oral; subject to first-pass metabolism); food does not significantly affect absorption.'"`UNIQ--ref-0000004C-QINU`"' |
| pregnancy | String | |
| legal | String |